At nearly two years post launch, close to 90% of nephrologists are using Veltassa compared to 61% of cardiologists and promotion could be a major factor in the difference between the specialties according to the latest quarterly update from Spherix…
Market access restrictions for these high efficacy therapies may be hindering their ability to optimally treat their clinically complex, relapsing patients, according to a new report from Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 15, 2017 /PRNewswire/ —…
New indication should bolster sales of Auryxia according to the latest reports from Spherix Global Insights Download Report Overview EXTON, Pa., Nov. 7, 2017 /PRNewswire/ — Earlier today Keryx announced the second approval for Auryxia (ferric citrate) to treat iron…
Over one in five psoriasis patients are reported to switch between biologics or Celgene’s Otezla to a different brand within a given year Download Report Overview EXTON, Pa., October 31, 2017 /PRNewswire/ — Spherix Global Insights announces the release of…
Use of biologic/JAK monotherapy is primarily driven by adequate patient response on monotherapy, tolerability issues with traditional DMARDs, or comorbidities preventing use, according to recent findings from Spherix Global Insights Download Report Overview EXTON, Pa., October 23, 2017 /PRNewswire/ —…
Half of all surveyed rheumatologists agree a new oral small molecule would be of greater use in psoriatic arthritis than any additional alternative mechanism of action biologic, according to recent findings from Spherix Global Insights Download Report Overview EXTON, Pa.,…